Introduction
Vivo Surgical is a patient-focused, clinically driven medical device developer and manufacturer. Headquartered in Singapore, with commercial and co-innovation partnerships across multiple international territories, the company is pioneering a novel endoscopic robot for complex endoluminal procedures in the gastrointestinal (GI) tract. Our multidisciplinary team brings deep expertise in biomedical engineering, endoscopy, and robotics, complemented by strategic guidance from industry leaders from major medical technology MNCs and expert clinical key opinion leaders (KOLs) in the field of therapeutic endoscopy. This unique combination positions Vivo Surgical at the forefront of surgical innovation in flexible endoscopic robotics for complex GI procedures. ISO 13485 certified and internationally accredited, including US FDA and European CE approvals, Vivo Surgical develops proprietary devices that address global medical needs through the innovative application of science and technology.
CSSD/IBCC Support
Recognizing China as a pivotal growth market, Vivo Surgical sought to establish a strong foothold in the country’s thriving Medtech sector. CSSD played a crucial role in facilitating our market entry and expansion by providing comprehensive support at every stage of our journey—from initial site selection to operational setup and business integration. “I still remember our meeting with the CSSD team. We were exploring site options in China, initially leaning towards the South. Their response was simple yet confident: ‘Set aside two days for Suzhou Industrial Park—leave the rest to us.’ After the visit, my colleague returned to Singapore with absolute clarity—SIP was the right choice.” One of the key factors that attracted us to SIP was its business-friendly environment, world-class infrastructure, and strong ecosystem for medical device innovation. CSSD’s deep understanding of the MedTech sector in China allowed us to navigate the complex regulatory landscape with greater ease, ensuring a seamless and efficient business registration process. Beyond administrative facilitation, CSSD provided invaluable strategic guidance, connecting us with key stakeholders, including local government agencies, industry leaders, and potential business partners. Their support extended to areas such as talent acquisition, supply chain integration, and regulatory compliance, all of which were critical to accelerating our growth in the Chinese market. Additionally, CSSD’s presence through IBCC in Singapore enabled us to maintain a direct link between our headquarters and our expansion efforts in China, fostering smoother coordination and resource allocation. The combination of SIP’s robust ecosystem and CSSD’s proactive support has provided a strong foundation for our long-term success in China.
Conclusion
Singapore’s longstanding involvement in SIP has been instrumental in fostering goodwill and credibility, opening doors for Vivo Surgical in China’s competitive Medtech landscape. The seamless business environment, coupled with CSSD’s hands-on support, has given us the confidence and capability to expand our operations efficiently. By establishing our presence in SIP, we have been able to leverage a well-established network of multinational medical device companies, a thriving supply chain ecosystem, and a talent pool of highly skilled professionals. This strategic move has not only enhanced our manufacturing and R&D capabilities but also positioned us at the forefront of flexible endoscopic robotics for complex GI procedures in China. As we continue to push the boundaries of surgical innovation and medical technology, CSSD remains a trusted partner in our journey. Their unwavering support has helped Vivo Surgical transform its vision into reality, paving the way for us to deliver groundbreaking solutions that improve patient outcomes worldwide. Vivo Surgical will continue to scale its innovations, forge new partnerships, and contribute to advancing the global Medtech industry.